Company Performance Metrics
Agrenvec is European biotech specialized in plant production of mammalian recombinant proteins and antibodies for the R&D market. Was created as a start-up company in 2002 with the in-licensing of several patents from the INIA (Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria).
They are focused on the development,
manufacture, and marketing, of products and services for the R&D and Industrial markets. Their Company owns a patented technology platform allowing us a high-throughput production of Animal-free fully active recombinant proteins with complex 3D structure and with a purity of 97%.
Supported by a multi-disciplinary group of experts with an extensive professional career, Agrenvec is one of the few companies in the world capable of using viral vectors technology to turn plants into bio-factories. It counts with a stable work team of fourteen highly qualified professionals, 30% of their personnel have a Ph.D. and 60% have a university degree. Their management team has a long experience in the pharmaceutical and biotechnological industry.
Their main offices and laboratories are located in the Parque Científico de Madrid. Their facilities are equipped with the latest technology in genetic engineering, the purification of proteins including last generation ÄKTA Explorer, ÄKTA Express, phytotron, and greenhouse for plant production and complete equipped molecular laboratory.
